Sulfonylureas and hypoglycaemia

Diabetes, Nutrition and Metabolism - Clinical and Experimental

Volumn 15, Issue 6, 2002, Pages 444-451

  Del Prato, Stefano ^a   Aragona, M ^a   Coppelli, A ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

Hypoglycaemia; Sulfonylureas; Type 2 diabetes

Indexed keywords

ACARBOSE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHLORPROPAMIDE; GLIBENCLAMIDE; GLICLAZIDE; GLIPIZIDE; GLUCOSE; INSULIN; INSULIN ASPART; INSULIN GLARGINE; INSULIN LISPRO; METFORMIN; NATEGLINIDE; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; REPAGLINIDE; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE; TOLAZAMIDE; TOLBUTAMIDE;

ADULT; AGED; CELL FUNCTION; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EXCRETION; DRUG METABOLISM; DRUG POTENCY; FEMALE; GLUCOSE BLOOD LEVEL; HORMONAL REGULATION; HORMONE RESPONSE; HUMAN; HYPOGLYCEMIA; INCIDENCE; INSULIN BLOOD LEVEL; INSULIN RELEASE; INSULIN RESISTANCE; KIDNEY DYSFUNCTION; MALE; METABOLIC REGULATION; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET CELL; PATIENT COMPLIANCE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; URINARY EXCRETION;

DIABETES MELLITUS, TYPE 2; HOMEOSTASIS; HUMANS; HYPOGLYCEMIA; INSULIN; MIDDLE AGED; SULFONYLUREA COMPOUNDS;

EID: 0036968532     PISSN: 03943402     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (31)

1. Amos A.F., McCarty D.J., Zimmet P.: The rising global burden of diabetes and its complications: estimates and projections to the year 2010. Diabet. Med. 14: S1-S85, 1997.
2. UK Prospective Diabetes Study (UKPDS) Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of compliations in patients eith type 2 diabetes (UKPDS 33). Lancet 352: 837-853, 1998.
3. Jennings A.M., Wilson R.M., Ward J.D.: Symptomatic hypoglycaemia in NIDDM patients treated with oral hypoglycaemiac agents. Diabetes Care 12: 203-208, 1989.
4. The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin dependent diabetes mellitus. N. Engl. J. Med. 329: 977-986, 1993.
5. Ferner R.E., Neil H.A.: Sulphonylureas and hypoglycaemia. Br. Med. J. 296: 949-950, 1988,
6. Shorr R.I., Ray W.A., Daugherty J.R., Griffin M.R.: Individual sulfonylureas and serious hypoglycaemia in older people. J. Am. Geriatr. Soc. 44: 751-755, 1996.
7. Berger W., Caduff F., Pasquel M., Rump A.: The relatively frequent incidence of severe sulphonylureas-induced hypoglycaemia in the last 25 years in Switzerland. Results of 2 surveys in Switzerland in 1969 and 1984. Schweiz. Med. Wochenschr. 116: 145-151, 1986
8. Dahlen M., Bergman U., Idman L., Martnsson L., Karlsson G.: Epidemiology of hypoglycaemia in patients on oral antidiabetic drugs in the island of Gotland, Sweden. Acta Endocrinol. 263 (Suppl.): A21, 1984.
9. Chan T.Y.K., Chan J.C.N., Tomlinson B., Critchley J.A.J.H.: Adverse reactions to drugs as a cause of admission to a teaching hospital in Hong Kong. Drug Saf. 7: 235-240, 1992.
10. Gill G.V., Huddle K.R.: Hypoglycaemic admissions among diabetic patients in Soweto, South Africa. Diabet. Med. 10: 181-183, 1993.
11. Levy C.J., Kinsley B.T., Bjaj M., Simonson D.C.: Effect of glycaemic control on glucose counterregulation during hypoglycaemia in NIDDM. Diabetes Care 21: 1330-1338, 1998.
12. Bolli G., Tsalikian E., Haymond M., Cryer P., Gerich J.: Defective glucose counterregulation after subcutaneous insulin in noninsulin-dependent diabetes mellitus. J. Clin. Invest. 73: 1532-1541, 1984.
13. Heller S.R., Macdonald I.A., Tattersall R.B.: Counterregulation in type 2 (non-insulin-dependent) diabetes mellitus: normal endocrine and glycaemic responses, up to ten years after diagnosis. Diabetologia 30: 924-929, 1987.
14. Shamoon H., Fridman S., Canton C., Zacharowicz L., Hu M., Rossetti L.: Increased epinephrine and skeletal muscle responses to hypoglycaemia in non-insulin-dependent diabetes mellitus. J. Clin. Invest. 93: 2562-2571, 1984.
15. Spyer G., Hattersley A.T., MacDonald I.A., Amiel S., MacLeod K.M.: Hypoglycaemic counter-regulation at normal blood glucose concentrations in patients with well controlled type-2 diabetes. Lancet 356: 1970-1974, 2000.
16. Meneilly G., Cheung E., Tuokko H.: Counterregulatory hormone responses to hypoglycaemia in the elderly patient with diabetes. Diabetes 43: 403-410, 1994.
17. Burge M.R., Schmitz-Fiorentino K., Fischette C., Qualls C.R., Schade D.S.: A prospective trial of risk factors for sulfonylurea-induced hypoglycaemia in Type 2 diabetes mellitus. J.A.M.A. 279: 137-143, 1998.
18. Asplund K., Wiholm B.-E., Lithner F.: Glibenclamide-associated hypoglycaemia: a report on 57 cases. Diabetologia 24: 412-417, 1983.
19. Van Staa T., Abenhaim L., Monette J.: Rates of hypoglycaemia in users of sulfonylureas. J. Clin. Epidemiol. 50: 735-741, 1997.
20. Ben-Ami H., Nagachandran P., Mendelson A., Edoute Y.: Drug-induced hypoglycaemic coma in 102 diabetic patients. Arch. Intern. Med. 159: 281-284, 1999.
21. Varas C., Rueda A.M.: Diabetes and renal impairment in the US elderly population. The Third National Health and Nutrition Examination Survey (NHANES III, 1988-1994) 2001. Epidemiologic report.
22. Trovati M., Burzacca S., Mularoni E., Massucco P., Cavalot F., Matiello L., Anfossi G.: Occurrence of low blood glucose concentrations during the afternoon in Type 2 (non-insulin-dependent) diabetic patients on oral hypoglycaemic agents: importance of blood glucose monitoring. Diabetologia 34: 662-667, 1991.
23. Dreager K.E., Wernicke-Panten K., Lomp H.J., Schuler E., Rosskamp R.: Long-term treatment of Type 2 diabetic patients with the new oral antidiabetic agent glimepiride (Ameryl): a double blind comparison with glibenclamide. Horm. Metab. Res. 28: 419-425, 1996.
24. Langtry H.D., Balfour J.A.: Glimepiride. A review of ist use in the management of Type 2 diabetes mellitus. Drugs 55: 563-584, 1998.
25. Del Prato S., Tiengo A.: The importance of the first-phase insulin secretion. Implications for the therapy of type 2 diabetes melitus. Diabetes Metab. Res. Rev. 17: 164-174, 2001.
26. Weyer C., Tataranni P.A., Bogardus C., Pratley R.E.: Insulin resistance and insulin secretory dysfunction are independent predictors of worsening of glucose tolerance during each stage of type 2 diabetes development. Diabetes Care 24: 89-94, 2001.
27. Bruttomesso D., Pianta A., Mari A., Valerio A., Marescotti M.C., Avogaro A., Tiengo A., Del Prato S.: Restoration of early rise in plasma insulin levels improves the glucose tolerance of type 2 diabetic patients. Diabetes 48: 99-105, 1999.
28. Tessier D., Dawson K., Tetrault J.P., Bravo G., Meneilly G.S.: Glibenclamide vs gliclazide in Type 2 diabetes of the elderly. Diabet. Med. 11: 974-980, 1994.
29. Smedegaard Kristensen J., Brown Frandsen K., Bayer T., Müller P.G.: Repaglinide treatment is associated with significantly less severe hypoglycaemic events compared to sulphonylureas. Diabetologia 42 (Suppl. 1): A4, 1999.
30. Hollander P., Schartz S.L., Gatlin M.R., Haas S.J., Zheng H., Foley J.E., Dunning B.E.: Importance of early insulin secretion. Comparison of nateglinide and glyburide in previously diet-treated patients with Type 2 diabetes. Diabetes Care 24: 983-988, 2001.
31. Browne D.L., Avery L., Turner B.C., Cavan D.A.: What do patients with diabetes know about their tablets? Diabet. Med. 17: 528-531, 2000.